Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eplerenone for Abnormal Hemodynamics After TAVR
NCT03923530Phase 1Completed
- Sponsor
- North Florida Foundation for Research and Education
- Start
- Jun 2019
- Primary completion
- Feb 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of eplerenone in hypertension (HTN) and diastolic dysfunction, sponsored by North Florida Foundation for Research and Education. Primary endpoint: Kansas City Cardiomyopathy Questionnaire Summary Score at 8 weeks. Started Jun 2019; status: completed.
02
Drugs
eplerenone
03
Conditions
hypertension (HTN)diastolic dysfunction
Beyond the preview
Go deeper on NCT03923530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03923530.